This bill proposes to classify xylazine as a schedule III controlled drug by amending the Controlled Drug Act (RSA 318-B). Specifically, it introduces a new section, 318-B:1-d, which states that xylazine shall be scheduled as a controlled substance, overriding the existing provisions that allow for scheduling by rulemaking from the commissioner of the Department of Health and Human Services. The bill does not delete any existing legal language but adds this new classification to the current law.

The act is set to take effect on January 1, 2027, and is expected to have indeterminable fiscal impacts on state and local expenditures due to potential changes in the judicial and correctional systems, including costs related to prosecution, incarceration, probation, and parole. However, it is projected that there will be no revenue generated from this bill. The bill has been reviewed by various agencies, including the Judicial Branch and the Department of Justice, to assess its implications.